MX2021012188A - Parasiticidas sistemicos de isoxazolina para el tratamiento o la profilaxis de enfermedades virales y transmitidas por vectores. - Google Patents

Parasiticidas sistemicos de isoxazolina para el tratamiento o la profilaxis de enfermedades virales y transmitidas por vectores.

Info

Publication number
MX2021012188A
MX2021012188A MX2021012188A MX2021012188A MX2021012188A MX 2021012188 A MX2021012188 A MX 2021012188A MX 2021012188 A MX2021012188 A MX 2021012188A MX 2021012188 A MX2021012188 A MX 2021012188A MX 2021012188 A MX2021012188 A MX 2021012188A
Authority
MX
Mexico
Prior art keywords
isoxazoline
vector
prophylaxis
viral
borne diseases
Prior art date
Application number
MX2021012188A
Other languages
English (en)
Spanish (es)
Inventor
Douglas Michael Ackermann
Shawn D Hickok
Bobak Robert Azamian
Christopher Stivers
Original Assignee
Tarsus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarsus Pharmaceuticals Inc filed Critical Tarsus Pharmaceuticals Inc
Publication of MX2021012188A publication Critical patent/MX2021012188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021012188A 2019-04-04 2020-04-03 Parasiticidas sistemicos de isoxazolina para el tratamiento o la profilaxis de enfermedades virales y transmitidas por vectores. MX2021012188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962829573P 2019-04-04 2019-04-04
PCT/IB2020/053229 WO2020202111A1 (en) 2019-04-04 2020-04-03 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis

Publications (1)

Publication Number Publication Date
MX2021012188A true MX2021012188A (es) 2022-02-11

Family

ID=72667108

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012188A MX2021012188A (es) 2019-04-04 2020-04-03 Parasiticidas sistemicos de isoxazolina para el tratamiento o la profilaxis de enfermedades virales y transmitidas por vectores.

Country Status (11)

Country Link
US (2) US20220160682A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946325A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022527359A (cg-RX-API-DMAC7.html)
KR (1) KR20220054241A (cg-RX-API-DMAC7.html)
CN (1) CN113993518A (cg-RX-API-DMAC7.html)
AU (2) AU2020251960A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019931A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136042A1 (cg-RX-API-DMAC7.html)
IL (1) IL286914A (cg-RX-API-DMAC7.html)
MX (1) MX2021012188A (cg-RX-API-DMAC7.html)
WO (1) WO2020202111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
US12502377B2 (en) * 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
CN111265528A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
WO2022079496A1 (en) * 2020-10-13 2022-04-21 Menschlich Healthcare Opc Private Limited A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof
CN112294793B (zh) * 2020-10-21 2022-03-22 青岛海洋生物医药研究院股份有限公司 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用
WO2022130031A1 (en) * 2020-12-17 2022-06-23 Chander Mohan Negi A pharmaceutical composition of nitazoxanide and mefloquine and method thereof
CN118420621A (zh) * 2021-02-07 2024-08-02 南京知和医药科技有限公司 一种磺酰胺类多环化合物及其制备方法与用途
US20250318529A1 (en) * 2022-05-16 2025-10-16 Syngenta Crop Protection Ag Method for mosquito control
WO2024168149A1 (en) * 2023-02-10 2024-08-15 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US20240366572A1 (en) * 2023-05-07 2024-11-07 Michael Farber Isoxazoline complexes and compositions thereof
US11903962B1 (en) * 2023-05-07 2024-02-20 Michael Farber Isoxazoline complexes and compositions thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI556741B (zh) * 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
US8313752B2 (en) * 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
CN110167540A (zh) * 2016-10-31 2019-08-23 斯克利普斯研究所 用于预防媒介传播疾病的传播的方法和组合物
WO2020051106A1 (en) * 2018-09-05 2020-03-12 Zoetis Services Llc Palatable antiparasitic formulations
BR112022000982A2 (pt) * 2019-07-22 2022-03-08 Intervet Int Bv Forma de dosagem veterinária mastigável macia

Also Published As

Publication number Publication date
US20220160682A1 (en) 2022-05-26
JP2022527359A (ja) 2022-06-01
AU2020251960A1 (en) 2021-11-11
WO2020202111A1 (en) 2020-10-08
CN113993518A (zh) 2022-01-28
AU2026205483A1 (en) 2026-07-30
CA3136042A1 (en) 2020-10-08
EP3946325A1 (en) 2022-02-09
KR20220054241A (ko) 2022-05-02
US20230218584A1 (en) 2023-07-13
IL286914A (en) 2021-10-31
JP2026083151A (ja) 2026-05-19
BR112021019931A2 (pt) 2021-12-07
EP3946325A4 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
BR112021019931A2 (pt) Parasiticidas isoxazolina sistêmicos para tratamento ou profilaxia de doença transmitida por vetor e viral
JOP20230326A1 (ar) أجزاء علاجية جديدة واستخداماتها
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
EA202091615A1 (ru) Интраназальные составы на основе эпинефрина и способы лечения заболевания
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
MX2021009239A (es) Tratamiento contra el cáncer con inmunoconjugados de anticuerpos ror1.
CY1115046T1 (el) Καινουργια sirnas και μεθοδοι χρησης αυτων
NZ737757A (en) Peptide oligonucleotide conjugates
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
WO2019217397A3 (en) Compositions and methods for improving strand biased
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
PH12021551421A1 (en) Tubulysins and protein-tubulysin conjugates
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
MX2018007307A (es) Conjugados de peptidos y oligonucleotidos.
ZA202302155B (en) Interferon-based cancer treatment method and pharmaceutical composition
MX2019005040A (es) Métodos y composiciones para prevenir la transmisión de enfermedades vectoriales.
MX2018008078A (es) Tecnologia de sinergismo anticuerpo-farmaco para el tratamiento de enfermedades.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2021000127A (es) Formulaciones de un inhibidor de axl/mer.
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2